REAL PRACTICE OF STATINS USE AND ITS DEPENDENCE ON FOLLOW-UP IN THE SPECIALIZED MEDICAL CENTRE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK (ACCORDING TO THE PROFILE REGISTER)

Aim. To analyze tactics of statins use in patients with high cardiovascular risk on the base of the PROFILE register data.
Material and methods. Patients (n=274) who were enrolled into the PROFILE register from May, 1st till December, 31st, 2011 were divided into 3 groups: a control group (82 patients who sought medical care in the medical centre for the first time), the main group A (167 patients who were regularly followed-up in the medical centre) and the main group B (25 patients who stopped follow-up in the medical centre over 2 years ago). The incidence rates of statins use and lipid target level achievement, as well as safety of statin therapy were studied in the groups.
Results. 25.6, 70.7 and 52% of patients received statins in control group, main group A, and main group B, respectively. Target levels (according to the clinical guidelines) of the low density cholesterol (LDC) had been reached in 26.3% of patients in the main group A. This characteristic was not valid in the patients of control and main group B because of small size of these groups. Achievement of target LDC level was observed more often in use of statins in moderate and high doses, use of the original drugs, and use of rosu- vastatin. Safety of statin therapy (aspartate and alanine transaminases, creatine kinase activity, and total bilirubin) was comparable in the groups of patients who reached or did not reach target LDC levels.
Conclusion. High cardiovascular risk patients who were regularly followed-up in the specialized medical centre received statins therapy significantly more often. However statins use is often not correspond to the modern clinical guidelines.

1. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dys- lipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–818.

2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high–risk individuals: a randomised placebo–controlled trial. Lancet 2002;360(9326):7–22.

3. Eagle KA, Montoye CK, Riba AL, et al. Guideline-Based Standardized Care Is Associated With Substantially Lower Mortality in Medicare Patients With Acute Myocardial Infarction: The American College of Car- diology’s Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 2005;46:1242-8.

4. Efficacy and safety of pharmacotherapy at primary and secondary prophylaxis of cardiovascular diseases. RSC Guidelines. The Rational Pharmacother Card 2011; 7 (5): 1-72. Russian (Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактики сердечно-сосудистых заболеваний. Рекомендации ВНОК. Рациональная Фармакотерапия в Кардиологии 2011; 7 (5): 1-72).

5. Yusuf S, Islam S, Chow CK, et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle- income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378(9798):1231-43.

6. Oganov R. G, Pogosova G. V, Koltunov I.E., et al. RELIF – regular treatment and prophylaxis a key to improvement of a situation with cardiovascular diseases in Russia: results of the Russian multicenter study. Part III. Kardiologiia 2008; 48 (4):46-53. Russian (Оганов Р.Г., Погосова Г.В., Колтунов И.Е. и др. РЕ- ЛИФ – РЕгулярное Лечение И проФилактика — ключ к улучшению ситуации с сердечно-сосудистыми заболеваниями в России: результаты российского многоцентрового исследования. Часть III. Кар- диология 2008;48(4):46-53)

7. Shalnova S.A., Deev A.D. Lesson of the OSCAR study – "The epidemiology and features of therapy of patients with high risk in real clinical practice 2005–2006 years". Cardiovascular Therapy and Prophylaxis 2007; 6 (1):47-53. Russian (Шальнова С.А., Деев А.Д. Уроки исследования ОСКАР – ЭпидемиОлогия и оСобенности терапии пациентов высоКого риска в реАльной клинической пРактике. 2005-2006 гг.» Кардиоваскулярная Терапия и Профилактика 2007; 6(1):47-53).

8. Susekov А.В, Zubarev M. Ju, Deev А.D, et al. The basic results of the Moscow Research on Statins (Moscow Statin Survey, MSS). Heart 2006; (6):324-328. Russian (Сусеков А.В, Зубарева М.Ю, Деев А.Д, и др. Основные результаты Московского Исследования по Статинам (Moscow Statin Survey, MSS). Сердце 2006; (6):324-328).

9. Martsevich S.J., Drozdova L.J., Lukina J.V., et al. As practical doctors of possibility of modern medicamental therapy sick of a chronic ischemic heart trouble estimate. Results of interrogations in Moscow and Voronezh. Rational Pharmacother Card 2010; 6 (2: 145-148). Russian (Марцевич С.Ю., Дроздова Л.Ю., Лукина Ю.В., и др. Как оценивают практические врачи возможности современной медикаментозной терапии больных хронической ишемической болезнью сердца. Результаты опросов в Москве и Воронеже. Рациональная Фармакотерапия в Кардиологии 2010; 6(2): 145-148).

10. Martsevich S.J., Gajsenok O. V, Tripkosh S.G., Zagrebelnj A.V., Lukina JU.V. Observation in the spe- cialised medical centre and quality hipolipidemic therapy in patients with cardiovascular diseases (according to the register the PROFILE). Rational Pharmacother Card 2013; 9 (2: 133-137). Russian (Мар- цевич С.Ю., Гайсенок О.В., Трипкош С.Г., Загребельнй А.В., Лукина Ю.В. Наблюдение в спе- циализированном медицинском центре и качество гиполипидемичекой терапии у пациентов с сердечно-сосудистыми заболеваниями (по данным регистра ПРОФИЛЬ). Рациональная Фармакотерапия в Кардиологии 2013; 9 (2): 133-137).

11. Lipson A., Fallis W., Wang X., Yi Y. Are patients with hyperlipidemia undertreated? Canadian Family Physician 2007; 53: 1503-1507.

12. Julian D. Translation of clinical trials into clinical practice. Journal of Internal Medicine 2004; 255: 309-316.

13. Martsevich S.J., Voronina V. P, Drozdova L.JU.health and formation of the doctor: two components of success. Rational Pharmacother Card 2010; 6 (1): 73-76. Russian (Марцевич С.Ю., Воронина В.П., Дроздова Л.Ю. Здоровье и образование врача: две составляющие успеха. Рациональная Фармакотерапия в Кардиологии 2010; 6 (1): 73-76).

14. Drozdova L.J., Martsevich S.J., Voronina V.P. Simultaneous evaluation of prevalence and efficacy of cor- rection of risk factors of cardiovascular diseases among doctors and their knowledge of modern clinical guidelines. Rational Pharmacother Card 2011; 7 (2):137-144. Russian (Дроздова Л.Ю., Марцевич С.Ю., Воронина В.П. Одновременная оценка распространенности и эффективности коррекции факторов риска сердечно-сосудистых заболеваний среди врачей и их знания современных клинических рекомендаций. Рациональная Фармакотерапия в Кардиологии 2011;7 (2):137-144).

15. Cannon C., Braunwald E., McCabe C. et al. Intensive versus Moderate Lipid Lowering with Statins af- ter Acute Coronary Syndromes. N Engl J Med 2004;350:1495-504.

16. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 sur- vivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376: 1658–69.